Marc Raaijmakers, Hartmut Döhner, Dimitri Breems, John Byrd, Konstanze Döhner, Jordi Esteve, Bjørn Gjertsen, Patrycja Gradowska, Gerwin A. Huls, Ain Kaare, Heeje Kim, Hitoshi Kiyoi, Mika Kontro, Janusz Krawczyk, Vladimir Lazarevic, Andrea Lenartova, Alice Mims, Jeannine Refos, Christoph Röllig, Anika Schrade, Karolina Sikorska, Alexandre Theocharides, Peter Valk, Adriano Venditti, Jianxiang Wang, Andrew Wei, Agnieszka Wierzbowska, Andrius Zucenka, Lucille Ferrante, Christina Drenberg Guttke, Angélique Langlois, Christina Loefgren, Kathryn Packman, Prathap Nagaraja Shastri, Natasha Schuier, Meena Thayu, Danielle Trancucci, Bob Lowenberg, Lars Bullinger. "Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)." Blood, 2025. doi:10.1182/blood-2025-1654